Education
Ph.D. - Neuroimmunology
The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences - Houston, Texas
August 2016 - May 2022
Cumulative GPA: 4.000
M.S. - Biotechnology
Texas Tech University Health Sciences Center - Abilene, Texas
August 2014 - May 2016
Cumulative GPA: 3.942
B.S. - Biochemistry
Angelo State University - San Angelo, Texas
Minor: Biology for Biochemistry majors
January 2010 - May 2014
Cumulative GPA: 3.724 Magna Cum Laude
Research Experience
ILC2s polarize microglia to a reparative, M2-like phenotype
Mentors: Drs. Jaroslaw “Jarek” Aronowski and Louise D. McCullough
The greatest risk factor for stroke is aging, which leads to a dysregulation of inflammatory responses throughout the body. Group 2 innate lymphoid cells (ILC2s) help balance inflammation in young mice but have not been investigated in aging. My dissertation investigated how ILC2s and brain immune cells, called microglia, communicate and how ILC2s can control microglia to be reparative in aging and age-related diseases such as stroke.
Development of a high-throughput assay to screen antibody and T cell selectivity/specificity against the peptide/human leukocyte antigen complex
Mentors: Drs. Devin B Lowe and Jon A Weidanz
Immunotherapy is a first-line strategy against several forms of cancer and a common Y-shaped protein, called antibodies, is currently used as a therapeutic for cancer and other diseases. All cells, except red blood cells, let the immune system know they are healthy or infected using a signal called the peptide/human leukocyte antigen (HLA), and our group have developed an antibody that can recognize this signal and bring either drugs or immune cells to specific diseased targets. Unfortunately, many therapeutics fail in clinical trials, highlighting the need for more rigorous pre-clinical testing. During my master’s degree, I developed a platform to analyze how our antibodies bind these peptide/HLA complexes using labeled and unlabeled techniques to identify the most selective antibodies, thereby decreasing off-target effects and increasing patient safety.
Isolation, sequence, and characterization of p53 mRNA in various bat species
Mentor: Dr. Loren K Ammerman
Bats live substantially long lives compared to other mammals of similar size but do not develop cancer. Tumor suppressors are one mechanism meant to protect the body from cancer. p53 is a commonly researched tumor suppressor with many different variants of this protein. My undergraduate research investigated the message that leads to the protein (mRNA) extracted from bats that I helped capture and preserve and mRNA sequences found in a database to compare p53 sequences between bats and other mammals. I discovered a unique insertion in 4 of the 5 bats in my alignment, though the biological importance of this region remains to be determined.
Certifications
Health and Human Services Regulations | U.S. Department of Health and Human Services | March 2021
Human Subjects Research | U.S. Department of Health and Human Services | March 2021
Independent Review of Research | U.S. Department of Health and Human Services | March 2021
Institutional Review Board | U.S. Department of Health and Human Services | March 20201
International Conference for Harmonisation E6(R2) Good Clinical Practice | TransCelerate BioPharma Inc. | March 2021
Phlebotomy | Central Texas Phlebotomy Institute, LLC. | April 2017